VivoSeq
Other

Open Fracture

1

Pipeline Programs

6

Active Trials

0

Companies Involved

Open Fracture is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

43/100

Attrition Rate

31/100

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs

Trial Status

13

clinical trials

Terminated3 · 23%
Completed3 · 23%
Not yet recruiting3 · 23%
Recruiting2 · 15%
Active, not recruiting1 · 8%
Withdrawn1 · 8%

Trial Activity

13 trials

Tobramycin Injection to Prevent Infection in Open Fractures
Active, not recruiting·MMassachusetts General Hospital·Phase 3·NCT04964947·600 enrolled
Volume Reduction for Open Fracture Irrigation
Not yet recruiting·IInova Health Care Services·Phase 4·NCT07437339·200 enrolled
Powdered Intrawound Vancomycin in Open Fractures Trial
Not yet recruiting·UUniversity of Manitoba·Phase 4·NCT06504992·350 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)